CGM Use in Heart Failure

NANot yet recruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Heart FailureDiabetes Mellitus
Interventions
DEVICE

Libre 2 rt-CGM

Freestyle Libre 2 consists of a sensor applied to the back of the upper arm. The sensor is a penny-sized flexible filament placed beneath the skin's surface to measure interstitial fluid. This sensor is applied utilizing a sensor applicator provided in the packaging. The sensor continuously reads interstitial glucose readings every minute and syncs with the Freestyle View app. The hypoglycemia alarm will be set to \< 80 mg/dl (for prevention of low blood glucose levels). Participants will be instructed to provide 15 grams of carbohydrates in response to a hypoglycemia alarm. The hyperglycemia alarm will be set at 300 mg/dl. Participants will call the research team if they experience repeated episodes \> 300 mg/dl (more than 2 episodes in a single day or 2 or more episodes in consecutive days). The research team will instruct the participant to check with their physician for a possible new insulin regimen, but they will be allowed to remain in the study.

DIAGNOSTIC_TEST

POC BG + Blinded CGM

Standard of care point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the study participation for up to 3 months.

Trial Locations (1)

30303

Grady Health System, Atlanta

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

American Heart Association

OTHER

collaborator

Abbott Diabetes Care

INDUSTRY

lead

Emory University

OTHER

NCT07045298 - CGM Use in Heart Failure | Biotech Hunter | Biotech Hunter